FABRICATION AND IN VITRO CHARACTERIZATION OF A NOVEL NANOSUSPENSION OF TELMISARTAN: A POORLY SOLUBLE DRUG PREPARED BY ANTISOLVENT PRECIPITATION TECHNIQUE USING 33 FACTORIAL DESIGN
Objective: The motivation behind the current examination was to build the solvency and dissolution rate of an antihypertensive drug telmisartan by the planning of nanosuspension by precipitation method at the research facility scale. We researched the nanoparticle manufacture of telmisartan employing a 33 factorial experimental configuration considering the impacts of nanosuspension on the physical, morphological, and dissolution properties of telmisartan.
Methods: To get ready, nanosuspension particles of an ineffectively dissolvable drug are moreover of a drug solution to the anti-solvent leads to abrupt supersaturation and precipitation the making of nanoparticles. The nanosuspension particles of a poorly soluble drug loaded with urea and surfactants (sodium lauryl sulfate (SLS), poloxamer 188, Tween 80) have been prepared by a precipitation method. The nanosuspension particles were characterized for particle size, zeta potential, Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), in vitro drug release, and release kinetics.
Results: The readily optimized batch nanosuspension particles evaluated and exhibited the particle size (750 nm), zeta potential (-24.33 mV), differential scanning calorimetry (DSC) drug exhibited a change in crystalline form to amorphous, in vitro dissolution (F12 was higher 95% within 5 min) and drug release kinetics. The formulation parameter of surfactant concentration is optimized.
Conclusion: The formulation of the nanosuspension approach has been shown to substantial improvement in the dissolution rate, thereby enhancing the oral bioavailability with the future development of this technology.
2. Wilkinson JM. Nanotechnology applications in medicine. Med Device Technol 2003;14:29-31.
3. Sharma P, Denny WA, Garg S. Effect of wet milling process on the solid-state of Indomethacin and simvastatin. Int J Pharma 2009;380:40-8.
4. Roco MC. Nanotechnology: convergence with modern biology and medicine. Curr Opin Biotechnol 2003;14:337-46.
5. Singh B, Chakkal KS, Ahuja N. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology. AAPS PharmSciTech 2006;7:19-28.
6. Verma S, Kumar S, Gokhale R, Burgess DJ. Physical stability of nanosuspensions: investigation of the role of stabilizers on ostwald ripening. Int J Pharm 2011;406:145-52.
7. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 2001;46:3-26.
8. Patel VR, Agrawal YK. Nanosuspension: an approach to enhance the solubility of drugs. J Adv Pharm Tech Res 2011;2:81-7.
9. Bilati U, Allemann E, Doelker E. Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues. AAPS PharmSciTech 2005;6:594-604.
10. Hassan MA, Suleiman MS, Najib NM. Improvement of the in vitro dissolution characteristics of famotidine by inclusion in ?-cyclodextrin. Int J Pharm 1990;58:19-24.
11. Urbanetz NA. Stabilization of solid dispersions of nimodipine and polyethylene glycol 2000. Eur J Pharm Sci 2006;28:67-76.
12. Tripathi KD. Essentials of medical pharmacology. 6th ed. New Delhi, India: Jaypee Brothers, Medical Publishers Pvt Limited; 2008.
13. Jacobs C, Kayser MO, Muller MRH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm 2000;196:161-4.
14. Li L, Kakran M, Sahoo NG, Judeh Z, Wang Y, Chong K, et al. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. Int J Pharm 2010;383:285-92.
15. Zhong J, Shen ZG, Yang Y, Chen JF. Preparation and characterization of uniform nanosized cephradine by the combination of reactive precipitation and liquid antisolvent precipitation under high gravity environment. Int J Pharm 2005;301:286-93.
16. Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ, et al. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm 2006;323:153-60.
17. Pandya VM, Patel JK, Patel DJ. Formulation, optimization and characterization of simvastatin nanosuspension prepared by nanoprecipitation technique. Der Pharm Lett 2011;3:129-40.
18. Jain V, Kare P, Jain D, Singh R. Development and characterization of mucoadhesive nanosuspension of ciprofloxacin. Acta Poloniae Pharm Drug Res 2011;68:273-8.
19. Pandey N, DrSah AN, Mahara K. Formulation and evaluation of floating microspheres of nateglinide. Int J Pharm Sci Res 2016;7:453-64.
20. Jassem NA, Rajab NA. Formulation and in vitro evaluation of azilsartan medoxomil nanosuspension. Int J Pharm Pharm Sci 2017;9:110-9.
21. Sumathi R, Tamizharasi S, Sivakumar T. Formulation and evaluation of polymeric nanosuspension of naringenin. Int J Appl Pharm 2017;9:60-70.
22. Anjane M, Agrawal S, Khan A. Formulation and evaluation of nanosuspension of Valsartan. Int J Curr Pharm Res 2018;10:68-74.
23. Singhvi G, Canchi A, Khosa A, Banerjee S, Dubey SK. Design and characterization of polymeric nanoparticles of pioglitazone hydrochloride and study the effect of formulation variables using QbD approach. Curr Nanomater 2017;2:162-8.
24. Zhao X, Zu Y, Li Q, Wang M, Zu B, Zhang X, et al. Preparation and characterization of camptothecin powder micronized by a supercritical antisolvent (SAS) process. J Supercritical Fluids 2010;51:412-9.
25. Li L, Kakran M, Sahoo NG, Judeh Z, Wang Y, Chong K, et al. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. Int J Pharm 2010;383:285-92.
26. Sreeramulu J, Reddy MS, Jayaraju A, Rafiyuddin M. Formulation and evaluation of sildenafil citrate nanosuspension. Int J Pharm 2016;6:137-42.
27. Revathi S, Dhanaraju MD. Optimization and characterization ezogabine-loaded nanosuspension for enhancement of bioavailability by “bottom-up” technology using 32 factorial design. J Drug Delivery Ther 2019;9:227-37.
28. Mothilal M, Krishna MC, Teja SPS, Manimaran V, Damodharan N. Formulation and evaluation of naproxen-eudragit® RS 100 nanosuspension using 32 factorial design. Int J Pharm Pharm Sci 2014;6:449-55.
29. Barar J, Salatin S, Jalali MB, Adibkia K, Milani MA, Jelvehgari M, et al. Formulation and evaluation of eudragit RL-100 nanoparticles loaded in-situ forming gel for intranasal delivery of rivastigmine. Adv Pharm Bull 2020;10:20-9.
30. Yang J, Liu Q, Mai Y, Gu X, Zhao Y, Di X, et al. A wet-milling method for the preparation of cilnidipine nanosuspension with enhanced dissolution and oral bioavailability. J Drug Delivery Sci Tech 2020;55:1773-2247.
31. Dhanalakshmi M, Nagajyothi N, Thenmozhi S, Natarajan R, Rajendran NN. Formulation and evaluation of pitavastatin nanosuspension. Int J Pharm Life Sci 2014;5:3318-24.
32. Deshkar SS, Sonkamble KG, Mahore JG. Formulation and optimization of nanosuspension for improving solubility and dissolution of gemfibrozil. Asian J Pharm Clin Res 2019;12:157-63.
33. Mahajan A, Kaur S. Design, characterization and pharmacokinetic studies of solid lipid nanoparticles of antihypertensive drug telmisartan. Int J Pharm Sci Res 2017;8:3402-12.
34. El-Sherbiny IM, Elbaz NM, Khalil IA, Abd-Rabou AA. Chitosan-based nano-in-microparticle carriers for enhanced oral delivery and anticancer activity of propolis. Int J Bio Macromol 2016;92:254-69.
35. Dahiya M, Pandey P. A brief review on inorganic nanoparticles. J Crit Rev 2016;3:18-26.
36. Ethiraj T, Sujitha R, Ganesan V. Formulation and in vitro evaluation of nanosuspension of glimepiride. Int J Pharm 2013;3:875-82.
37. Murthy KVR, Raju V. Development and validation of new discriminative dissolution method for carvedilol tablets. Indian J Pharm Sci 2011;73:527-36.
38. Bajaj A, Rao MRP, Pardeshi A, Sali D. Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan. AAPS PharmSciTech 2012;13: 1331-40.
39. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-33.
40. Ramteke KH, Dighe PA, Kharat AR, Patil SV. Mathematical models of drug dissolution: a review. Sch Acad J Pharm 2014;3:388-96.
41. Peppas NA, Sahlin JJ. A simple equation for the description of solute release. coupling of diffusion and relaxation. Int J Pharm 1989;57:169-72.
42. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Delivery Rev 2012;64:163-74.
43. Abbas HK, Abood AN, Fatimah M, Wais H. Preparation and evaluation of ketoprofen nanosuspension using solvent evaporation technique. Iraqi J Pharm Sci 2017;26:41-55.
44. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Int J Pharm 2008;364:328-43.
This work is licensed under a Creative Commons Attribution 4.0 International License.